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Optics has consistently been the largest singular technology
sector used in medicine, and major advances in biomedical
optics are documented daily in peer-reviewed publications.
However, the academic stature of this field can be damaged
by weaknesses in scientific publishing, where a “credibility
crisis” has emerged as a popularized and increasingly
studied dialogue. While there are still relatively few overt
cases of fraud or erroneous research, more insidious
aspects are seen in papers with results that have either
low statistical power, selective reporting of observations, or
data or computer codes that cannot be independently verified.
Interestingly, the same solutions that improve scientific
publishing quality and credibility can also be effective tools
to foster growth of individual scientists. The solution for our
biomedical optics community is to ensure that researchers
allow and promote reproduction of results, effectively provide
access to original data and computer codes, and stay actively
involved in translating their results into practice. Along the
way, researchers should benefit from transdisciplinary collab-
orations and mentoring networks of colleagues, involving both
medical and commercial expertise. Publishing more impactful
publications makes the entire field more impactful, through a
sequence of quality measures and a focus on translation to
improve industry and medicine.
1 The Credibility Problems in Scientific
Publishing
The nature of the scientific publishing credibility problem is in
two distinct areas. The first is in the aspect of the highest
impact journals, where career pressures and financial pro-
grams have created a situation where the intensity of desire
to publish is driven by nonscientific goals.1 There have been
high-profile retractions of fraudulent papers, and less acute
but equally problematic lack of successes in translating
therapeutics when going from basic animal studies to
human clinical trials.2 The highest profile retractions have
been documented by the journals themselves in recent
years and publicized on websites,1,3 with some independent
meta-analyses undertaken to understand the scope of the
problem. The second distinct problem is at the bottom end
of the journal impact range, where there has been enormous
growth of journals with questionable credibility, willing to pub-
lish low-quality materials for a price with minimal or no real
peer review.4 These two issues are separate, but both are
symptoms of a system that is losing touch with core principles
and appropriate driving influences of an open scientific
community.
The high impact factor (IF) journal credibility crisis has
been a growing and openly debated issue, documented by
some of the same leading publishers. A poll of Nature readers
indicated that 90% of respondents thought there was a cred-
ibility crisis in their own published papers, with 52% indicating
it was a significant crisis.1 This self-reported survey has been
backed by scientific meta-analysis studies verifying the mag-
nitude of the problem, but others also argue that it remains in
proportion to the number of articles published.5 There have
been major discussion panels sponsored to try and solve
these issues, leading to white papers and proposed methodo-
logical solutions.6 Ultimately it is still up to each publisher to
self-police their credibility. But societal and governmental
bodies can get involved when expensive drugs fail to suc-
cessfully translate from the preclinical or early clinical
phase into pivotal trials. These are the most visible failures,
and the most costly for companies and funding agencies,
where the cost is ultimately to all of society. However,
while there are clearly high-profile investigations and retrac-
tions from fraudulent research activities, most argue that
these are still rare events, and the more insidious concerns
are those where authors are accused of selective reporting,
low statistical power, lack of self-replication, and insufficient
oversight or mentoring of junior scientists doing the work
and writing the papers. These factors, combined with pres-
sures to publish for career success, lead to some irreprodu-
cible papers that make it through the peer-review system. The
problem becomes further amplified by some local institutional
or governmental financial systems that provide financial
incentives for individual papers being published in high impact
factor journals,7 thereby prioritizing short-term successes over
long-term productivity goals, where quality and longevity of
success might be better assessed. The more measured
reward system of grant funding and scientist promotions
over years provides a balance over multiple or sustained suc-
cesses, which rewards achievements with demonstrated lon-
gevity over quick publication successes, and can take into
account a better measure of quality metrics such as citation
rates and translation efficacy of discoveries.8,9
The growth of low-impact journals is also well documented
through grassroots efforts to identify so-called “predatory jour-
nals,” which have the phenotype of low or absent standards
for review.10–12 There has been a robust grassroots effort to
highlight these journals,13,14 which can be identified by a num-
ber of features, such as the lack of an editorial board, lack of
transparency in their website and publisher identity, and lack
of indexing in known services such as Medline. Still, the
number of these journals has ballooned, and while there
are many shades of grey in validity, estimates indicate
there are nearly 8000 such journals. Most obviously, these
journals may not appropriately peer review their published© 2019 Society of Photo-Optical Instrumentation Engineers (SPIE)
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papers. Unfortunately, the scientists who are predisposed to
submit to these journals are often the most marginalized, by
being located at low-resource countries or institutions, or jun-
ior investigators whose guidance and motivations may not be
well placed.11,15 It is critical for the development of these indi-
viduals, and for the field itself, to provide guidance on optimal
routes for peer review and to help provide mentorship on the
appropriate ways to complete and sustain impactful science.
The easiest way for scientists to know if the journal that
they are submitting to is appropriate for them is to be
aware of the other peer scientists in their field and choose
journals that their peers use,14 and to focus on publishing
with their community. This process contributes to the overall
development of a network scientists who are working toward
competitive success with each other. But beyond the single
publishing event, the key linkage from scientist to scientist
is the broader idea that scientific research requires open
scholarly communication as well as scholarly competition.
This is the missing ingredient that must be continually
refreshed and renewed in our community, helping the field
focus on long-term gains and successes instead of individual
publishing events. The transition of the Journal of Biomedical
Optics to fully open access and the ability to include supple-
mentary materials with the original manuscript is the right
direction for our field, so that all research can be fully under-
stood and reproduced. We need to encourage our community
to be open with their work, to ensure reproducibility and trans-
parency in the process of promoting discoveries and
developments.
2 Accurate Measures of Success in
Translational Research
The changes that are occurring in the publishing world need
attention, but these shifts indicate that attention must also be
paid to broader measures of success in scientific discovery,
providing a reward system that has the right balance. The dis-
cussion is paralleled by a related issue, which is about how to
evaluate scientists as they come up for tenure and promotion.
Recently, a report by Ioannidis and Khoury16 proposed a new
set of metrics for assessing success over the long term, pro-
posing their PQRST approach, where this acronym repre-
sents the five metrics of productivity, quality, reproducibility,
sharing, and translation, as outlined in Table 1. This set of
metrics works quite well for a translational field such as bio-
medical optics.
These goals for measuring impact are all features of an
academic pipeline for a translational researcher, who is seek-
ing to go from publishing through to eventual translation. They
form an outstanding way to think about the successes of an
individual researcher, a research institute, or a scientific com-
munity publication. The steps in this sequence where the pub-
lishing world can help is to ensure that reproducibility and
sharing are possible. Reproducibility must be part of the
assessment of a published paper, with appropriate repeats
of data, based upon the known or expected variance in it.
Adjudicating this variance and repeatability is a key part of
editing and reviewing a paper. Sharing of data, computer
codes, materials, and protocols can be enforced by a pub-
lisher as a requirement to publish or can be stressed by
reviewers and editors. Biomedical optical devices are often
produced with unique algorithms, with competitive research
intensity focused on making better algorithms than others
in the field. In the end, these algorithms should either be freely
available or commercialized, such that others can use them to
validate the results. Without this level of transparency, it can
lead to publications that lack merit or believability. Similarly, if
there are unique data sets that would be required to reproduce
the work, it seems logical that they need to be made available
to others, so that the work can be fairly reviewed or repro-
duced. The field of biomedical optics should seriously con-
sider these goals, as is happening in other fields.17,18
The focus on eventual translation in biomedical optics is a
goal for most studies, where this can mean translation either
to industry development or to human clinical trial testing.19–21
Ultimately if both are successful, a new optical device can
change clinical practice by improving outcomes of the
patients. There are many examples of such optical devices
throughout surgery, pathology, cardiology, and all aspects
of medicine. By ensuring that quality, reproducibility, and
sharing are possible, journals can improve the impact of
the scientist’s discovery as well as the journal itself.
3 Translational Science Networks
In the field of biomedical optics, there is extreme geographic
and scientific diversity, together with aspects of the work in
the disparate areas of academia including medicine and
industry,22 and so it can be a challenge to promote collabora-
tion and cooperation in this setting where successes are mea-
sured by individual events such as publishing, grant funding,
and commercial triumphs. However, the features that benefit
individual researchers can be the same ones that benefit the
field as a whole, namely strong mentor networks of collabo-
rative researchers, who have a healthy balance of competition
and collaboration. Sharing data and algorithms is not neces-
sarily in conflict with individual innovation and successes;
rather, focusing on one without the other at all can lead to sus-
picion of publications and results. In translational science, the
local environment is critical—where solid biomedical optics
inventions require a three-way blend in academics-medi-
cine-industry—incorporating not just communication but
active participation. One of the most tangible features of
more integrated collaboration is the ability to efficiently cut
off projects that may not be beneficial or have a viable trans-
lation conduit. The biomedical optics field today has matured
Table 1 The five metrics in the PQRST approach.
P Productivity publications, continuity of output, output
per funded project, outreach
Q Quality citation metrics, longevity of value,
documented quality standards
R Reproducibility repeated measures, repeated by others
S Sharing data, computer code, materials,
protocols
T Translation in vitro → in vivo → human trial →
startup → industry → level 1 evidence
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to the point where there is extremely high creativity and a wide
diversity of topics; however, the number of discoveries that
penetrate out to viable medical devices and procedures still
can be a small fraction of this whole activity. Indeed, it is ap-
parent that most clinical optical devices use 40-year-old tech-
nologies of lamps, lenses, and glass fibers, because they are
reliable and inexpensive. As money and time is spent on
translational devices, hard decisions need to be made
about what works, incorporating all aspects of technical per-
formance, medical need, and commercial viability.22 If these
were all truly folded into every research program, we could
likely realize improved money spent on those programs
that match the needed goals and possibilities.19,20 To achieve
this, it would be good for developing researchers to have
stronger mentorship and advice on where focused efforts
were needed. This does not need to displace technical inno-
vation, but rather should complement it in an ongoing dia-
logue, which is often done in translational centers or in
networks program grants.23 One of the indicators that this is
happening to some extent is the documented growth in dual-
PI grants at the U.S. National Institutes of Health, as well as
industry-academic partnership program funding.24
4 Initiatives at the Journal of Biomedical
Optics
Some argue the problem is that the peer-review system is bro-
ken, leading to publications without true peer review and feed-
back. While this can be true in some fields and for some
journals, the strength of the SPIE BiOS community is the
enormous size and growth of the field, leading to a strong
desire to be part of it. This journal has a large and recently
expanded editorial board, which represents the diversity of
our field, in gender, geographic submissions, and research
topics.25 The long-term impact of papers published here
are still the highest of all biomedical optics journals today,
and the peer-review system metrics appear strong. Papers
published routinely get lengthy feedback, and still most
papers that have been accepted and pass quality-control
checks to enter the external peer-review system eventually
gain publication after productive revisions. This process of
a community-focused biomedical optics journal ensures
that the individuals in the field assist in the process of making
our science stronger.
A recent addition to the journal is the Perspective review
series of papers, which provides a conduit for guidance from
expert medical professionals to describe their vision for what
technologies are needed, to hopefully foster more of a two-
way dialogue.26 Those who wish to participate should volun-
teer, participate in the forum, and seek ways to ensure that we
provide strong friendly competition while not losing sight of the
need for collaboration and mentoring. Additionally, the BiOS
conference itself has become the world’s largest event for bio-
medical optics researchers to meet and present to each other.
While this is just one annual opportunity for exchange, it is
a critical piece of our overall community blending together
engineering academics, medical professionals, and industry.
I urge all involved in the field to work positively toward discov-
eries and innovations that are scientifically verifiable, translat-
able, and ultimately impactful to industry and medicine.
This journal is one important part of the overall efforts of
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